Evidence map›Paper›PMID 35709296›Full record

ArticlePLoS pathogens2022

RANBP2 and USP9x regulate nuclear import of adenovirus minor coat protein IIIa.

Ashrafali M Ismail, Amrita Saha, Ji S Lee, David F Painter, Yinghua Chen, Gurdeep Singh, Gabriela N Condezo, James Chodosh, Carmen San Martín, Jaya Rajaiya

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ashrafali M IsmailDepartment of Ophthalmology, Viral Pathogenesis Laboratory, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States of America.
Amrita SahaDepartment of Ophthalmology, Viral Pathogenesis Laboratory, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States of America.
Ji S LeeDepartment of Ophthalmology, Viral Pathogenesis Laboratory, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States of America.
David F PainterDepartment of Ophthalmology, Viral Pathogenesis Laboratory, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0003-4987-0448
Yinghua ChenDepartment of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio, United States of America.
Gurdeep SinghDepartment of Ophthalmology, Viral Pathogenesis Laboratory, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0003-2519-0456
Gabriela N CondezoDepartment of Macromolecular Structures, Centro Nacional de Biotecnología, Madrid, Spain.
James ChodoshDepartment of Ophthalmology, Viral Pathogenesis Laboratory, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States of America.
Carmen San MartínDepartment of Macromolecular Structures, Centro Nacional de Biotecnología, Madrid, Spain.
Jaya RajaiyaDepartment of Ophthalmology, Viral Pathogenesis Laboratory, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0002-4559-5613
Massachusetts Eye and Ear Infirmary · USCentro Nacional de Biotecnología · ESCase Western Reserve University · US

Funding

P30 Core Grant for Vision ResearchP30EY014104 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Janey L Wiggs · 2002 to 2026
$15.1M
Immunopathogenesis of Adenovirus KeratitisR01EY013124 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI James Chodosh, Jaya Rajaiya · 2001 to 2026
$10.8M
Novel Mechanisms in Adenoviral Ocular PathogenesisR01EY021558 · NEI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI James Chodosh, Jaya Rajaiya · 2011 to 2026
$7.1M
NEI NIH HHS P30 EY014104NEI NIH HHS R01 EY013124NEI NIH HHS R01 EY021558
6 · The paper itself

Abstract

As intracellular parasites, viruses exploit cellular proteins at every stage of infection. Adenovirus outbreaks are associated with severe acute respiratory illnesses and conjunctivitis, with no specific antiviral therapy available. An adenoviral vaccine based on human adenovirus species D (HAdV-D) is currently in use for COVID-19. Herein, we investigate host interactions of HAdV-D type 37 (HAdV-D37) protein IIIa (pIIIa), identified by affinity purification and mass spectrometry (AP-MS) screens. We demonstrate that viral pIIIa interacts with ubiquitin-specific protease 9x (USP9x) and Ran-binding protein 2 (RANBP2). USP9x binding did not invoke its signature deubiquitination function but rather deregulated pIIIa-RANBP2 interactions. In USP9x-knockout cells, viral genome replication and viral protein expression increased compared to wild type cells, supporting a host-favored mechanism for USP9x. Conversely, RANBP2-knock down reduced pIIIa transport to the nucleus, viral genome replication, and viral protein expression. Also, RANBP2-siRNA pretreated cells appeared to contain fewer mature viral particles. Transmission electron microscopy of USP9x-siRNA pretreated, virus-infected cells revealed larger than typical paracrystalline viral arrays. RANBP2-siRNA pretreatment led to the accumulation of defective assembly products at an early maturation stage. CRM1 nuclear export blockade by leptomycin B led to the retention of pIIIa within cell nuclei and hindered pIIIa-RANBP2 interactions. In-vitro binding analyses indicated that USP9x and RANBP2 bind to C-terminus of pIIIa amino acids 386-563 and 386-510, respectively. Surface plasmon resonance testing showed direct pIIIa interaction with recombinant USP9x and RANBP2 proteins, without competition. Using an alternative and genetically disparate adenovirus type (HAdV-C5), we show that the demonstrated pIIIa interaction is also important for a severe respiratory pathogen. Together, our results suggest that pIIIa hijacks RANBP2 for nuclear import and subsequent virion assembly. USP9x counteracts this interaction and negatively regulates virion synthesis. This analysis extends the scope of known adenovirus-host interactions and has potential implications in designing new antiviral therapeutics.

Indexed as

Adenoviridae InfectionsAdenoviruses, HumanCOVID-19Active Transport, Cell NucleusAdenoviridaeHumansMolecular ChaperonesNuclear Pore Complex ProteinsRNA, Small InterferingUbiquitin-Specific ProteasesUbiquitin ThiolesteraseViral ProteinsMolecular ChaperonesNuclear Pore Complex Proteinsran-binding protein 2RNA, Small InterferingUbiquitin-Specific ProteasesUbiquitin ThiolesteraseUSP9X protein, humanViral Proteins

Identifiers

PMID35709296
PMCPMC9242475
OpenAlexW4282967782

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.